Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can block cancer growth
in different ways. Some block the ability of cancer cells to grow and spread. Others find
cancer cells and help kill them or carry cancer-killing substances to them. Giving
alemtuzumab together with rituximab may kill more cancer cells.
PURPOSE: This phase II trial is studying the side effects and how well giving alemtuzumab
together with rituximab works in treating patients with high-risk, early-stage chronic
lymphocytic leukemia.